2-Bromo-5-fluoro-6-methylpyridine | CAS:374633-38-2

We serve 2-Bromo-5-fluoro-6-methylpyridine CAS:374633-38-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-5-fluoro-6-methylpyridine

Chemical Name:   2-Bromo-5-fluoro-6-methylpyridine
CAS.NO: 374633-38-2
Synonyms:6-Bromo-3-fluoro-2-methyl pyridine;
6-bromo-3-fluoro-2-methylpyridine;
Molecular Formula: C6H5BrFN
Molecular Weight: 190.01300
 
Physical and Chemical Properties:
Density: 1.6±0.1 g/cm3
Melting point: 63-65ºC
Boiling point: 183.4±35.0 °C at 760 mmHg
Flash point: 64.7±25.9 °C
Index of Refraction: 1.530
 
Specification:
Appearance:  White Crystalline Powder
Purity:≥98.0%
 
Packing:25 KGS/Drum
Storage:Store in a tightly closed container. Store in a cool, dry
Application:   used in the Pharmaceutical intermediate



Contact us for information like 2-Bromo-5-fluoro-6-methylpyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-bromo-3-fluoro-2-methylpyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromo-3-fluoro-2-methyl pyridine Use and application,2-Bromo-5-fluoro-6-methylpyridine technical grade,usp/ep/jp grade.


Related News: CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion.5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine manufacturer 3-Amino-5-Bromo-2-Methoxypyridine supplier 2-[2-(2-Methoxyphenoxy)ethyl]-1H-isoindole-1,3(2H)-dione vendor The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry.“With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”